Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 1,429 | 252 | 1,164 |
| Samples | 1,234 | 216 | 1,011 |
| Peptides | 928 | 158 | 811 |
Function
GRIN2B · Glutamate ionotropic receptor NMDA type subunit 2B
This gene encodes a member of the N-methyl-D-aspartate (NMDA) receptor family within the ionotropic glutamate receptor superfamily. The encoded protein is a subunit of the NMDA receptor ion channel which acts as an agonist binding site for glutamate. The NMDA receptors mediate a slow calcium-permeable component of excitatory synaptic transmission in the central nervous system. The NMDA receptors are heterotetramers of seven genetically encoded, differentially expressed subunits including NR1 (GRIN1), NR2 (GRIN2A, GRIN2B, GRIN2C, or GRIN2D) and NR3 (GRIN3A or GRIN3B). The early expression of this gene in development suggests a role in brain development, circuit formation, synaptic plasticity, and cellular migration and differentiation. Naturally occurring mutations within this gene are associated with neurodevelopmental disorders including autism spectrum disorder, attention deficit hyperactivity disorder, epilepsy, and schizophrenia. [provided by RefSeq, Aug 2017].
Isoforms & Proteins
1 transcript · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000609686 | Q13224 | 1,429 | 928 |
Gene Properties
Recurrent Mutations
All 928 amino-acid changes on canonical ENST00000609686 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in GRIN2B · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in GRIN2B – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Chronic Myelogenous Leukemia | 4/25 16% | 0/0 0% |
| T-Lymphoblastic Leukemia | 6/40 15% | 0/0 0% |
| Melanoma | 28/210 13% | 206/1899 11% |
| Non-Small Cell Lung Carcinoma | 34/304 11% | 92/1390 7% |
| Endometrial Carcinoma | 6/42 14% | 42/612 7% |
| Squamous Cell Lung Carcinoma | 9/57 16% | 54/810 7% |
| Glioblastoma | 5/98 5% | 0/0 0% |
| Other Solid Cancers | 5/94 5% | 71/1515 5% |
| Neuroendocrine Tumour | 18/154 12% | 15/577 3% |
| Acute Myeloid Leukemia | 4/90 4% | 0/0 0% |
| Small Cell Lung Carcinoma | 1/9 11% | 32/752 4% |
| T-Cell Non-Hodgkins Lymphoma | 1/26 4% | 0/0 0% |
| Hodgkins Lymphoma | 2/16 12% | 3/122 2% |
| Colorectal Carcinoma | 29/143 20% | 83/3239 3% |
| Gastric Carcinoma | 4/74 5% | 54/1809 3% |
| Cervical Carcinoma | 1/35 3% | 13/422 3% |
| Head and Neck Carcinoma | 5/85 6% | 35/1574 2% |
| Bladder Carcinoma | 5/58 9% | 18/956 2% |
| Mesothelioma | 2/62 3% | 3/165 2% |
| Esophageal Squamous Cell Carcinoma | 3/51 6% | 52/2550 2% |
| Germ Cell Tumour | 2/25 8% | 2/169 1% |
| Plasma Cell Myeloma | 2/44 5% | 5/305 2% |
| Other Sarcomas | 7/69 10% | 7/699 1% |
| Esophageal Carcinoma | 0/23 0% | 14/769 2% |
| Ovarian Carcinoma | 7/109 6% | 12/998 1% |
| Non-Cancerous | 3/104 3% | 11/830 1% |
| Glioma | 0/52 0% | 32/2127 2% |
| Biliary Tract Carcinoma | 0/54 0% | 11/950 1% |
| Breast Carcinoma | 4/144 3% | 33/3264 1% |
| Kidney Carcinoma | 0/85 0% | 20/1862 1% |
Mutation Distribution
Where GRIN2B is mutated · all tissues, split by cell line vs tissue
How many mutations in GRIN2B were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 1,429 mutations in GRIN2B
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|